Related Experiment Videos
Development of TGF-beta resistance during malignant progression.
1Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892-5055, USA.
Archives of Pharmacal Research
|March 11, 1999
Summary
Transforming growth factor-beta type II receptor (TGF-beta RII) mutations are common in epithelial cancers. These mutations in TGF-beta RII, a tumor suppressor gene, are critical steps in cancer development.
Area of Science:
- Molecular Biology
- Cellular Biology
- Oncology
Background:
- Transforming growth factor-beta (TGF-beta) is a key cytokine regulating cell proliferation and differentiation.
- TGF-beta's cellular effects depend on TGF-beta receptors (Types I, II, and III).
- Aberrant receptor expression and function are linked to human pathologies.
Purpose of the Study:
- To investigate the role of TGF-beta receptors in human pathology.
- To examine the susceptibility of the TGF-beta type II receptor (RII) coding sequence to DNA replication errors.
- To establish TGF-beta RII as a tumor suppressor gene.
Main Methods:
- Analysis of TGF-beta RII gene mutations.
- Observation of mutation levels in various malignancies.
Main Results:
- The TGF-beta RII coding sequence is uniquely susceptible to DNA replication errors.
- High mutation levels in the TGF-beta RII gene are observed in epithelial malignancies.
- Colon and gastric cancers show significant TGF-beta RII gene mutations.
Conclusions:
- TGF-beta RII functions as a tumor suppressor gene due to its role in cell proliferation regulation.
- Mutation of the TGF-beta RII gene is a critical step in carcinogenesis.
- TGF-beta RII mutations are prevalent in epithelial cancers.